Abstracts tagged "osteoarthritis and phenotypes"

Abstract Number: 288 • 2016 ACR/ARHP Annual Meeting
Glucose Homeostasis Influences the Risk of Incident Knee Osteoarthritis
Jeffrey Driban¹, Charles B. Eaton², Mamta Amin³, Alina Stout⁴, Lori Lyn Price⁵, Bing Lu⁶, Grace H. Lo⁷, Timothy E. McAlindon⁸ and Mary Barbe⁹, ¹Tufts Medical Center, Boston, MA, ²Family Medicine and Community Health( Epidemiology), Alpert Medical School of Brown University, Pawtucket, RI, ³Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, ⁴Rheumatology, Tufts Medical Center, Boston, MA, ⁵Clinical Care Research, Tufts Medical Center, Boston, MA, ⁶Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁷Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ⁸Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁹Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Knee osteoarthritis (KOA), particularly accelerated KOA, is associated with older age and being overweight. Greater age and weight are associated with impaired glucose homeostasis…
Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen², Jeppe Andersen³, Christian S. Thudium⁴, Bente J. Riis², Claus Christiansen², Hans Guehring⁵, Martin Michaelis⁵, Christoph Ladel⁵ and Morten Asser Karsdal⁶, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Merck KGaA, Darmstadt, Germany, ⁶Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…
Abstract Number: 1020 • 2016 ACR/ARHP Annual Meeting
Risk Factors Can Classify Individuals Who Develop Accelerated Knee Osteoarthritis
Jeffrey Driban¹, Timothy E. McAlindon², Mamta Amin³, Lori Lyn Price⁴, Charles B. Eaton⁵, Julie Davis⁶, Bing Lu⁷, Grace H. Lo⁸, Jeffrey Duryea⁹ and Mary Barbe¹⁰, ¹Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, ⁴Clinical Care Research, Tufts Medical Center, Boston, MA, ⁵Family Medicine and Community Health( Epidemiology), Alpert Medical School of Brown University, Pawtucket, RI, ⁶Rheumatology, Tufts Medical Center, Boston, MA, ⁷Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁸Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ⁹Radiology, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA, ¹⁰Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Accelerated knee osteoarthritis (KOA) is a painful disorder and associated with several risk factors: greater age, greater body mass index (BMI), static knee alignment,…
Abstract Number: 2401 • 2015 ACR/ARHP Annual Meeting
Identification and Characterization of Two Osteoarthritis Phenotypes Applying Two Clinically Tested Biomarkers
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen³, Bente J. Riis², Claus Christiansen², Morten Asser Karsdal¹ and Jeppe Andersen², ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Research & Development, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The osteoarthritis (OA) population is heterogeneous and it is therefore difficult to target all patients with the same intervention. Thus there is a clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].